SML3792

MRIA9 Trifluoroacetate

≥96% (HPLC)

• 別名: 8-(((2r,5r)-5-Amino-1,3-dioxan-2-yl)methyl)-6-(2-chloro-4-(3-fluoropyridin-2-yl)phenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one trifluoroacetate, 8-[(trans -5-Amino-1,3-dioxan-2-yl)methyl]-6-[2-chloro-4-(3-fluoro-2-pyridinyl)phenyl]-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one trifluoroacetate
• 実験式（ヒル表記法）: C₂₄H₂₂ClFN₆O₃ · xC₂HF₃O₂
• 分子量: 496.92 (free base basis)
• MDL番号: MFCD34474245
• UNSPSCコード: 12352200
• NACRES: NA.21

特性

• 品質水準: 100
• アッセイ: ≥96% (HPLC)
• フォーム: powder
• 保管条件: desiccated
• 色: white to beige
• 溶解性: DMSO: 2 mg/mL, clear
• 保管温度: -10 to -25°C
• SMILES記法: Fc1c(nccc1)c2cc(c(cc2)C3=Cc4c(nc(nc4)NC)N(C3=O)C[C@@H]5OC[C@H](CO5)N)Cl
• InChI Key: QKNBRNSGPNCARD-SGNKCFNYSA-N

詳細

生物化学的／生理学的作用

ATP site-targeting, dual salt-inducible kinase (SIK1/2/3) & p21-activated kinase (PAK2/3) inhibitor with excellent selectivity over other kinases.

MRIA9 is an ATP site-targeting, dual salt-inducible kinase (SIK1/2/3 IC50 = 55/48/22 nM; SIK2/3 IC50 = 180/127 nM by cell-based NanoBRET) & p21-activated kinase (PAK2/3 IC50 = 41/140 nM; PAK1 IC50 = 580 nM) inhibitor with excellent selectivity over other kinases. MRIA9 sensitizes ovarian cancer cells to mitotic agent paclitaxel (Pac) treatment in SKOV3 cultures (1 nM Pac plus 0.5-5 µM MRIA9) and HeLa spheroids (2 nM Pac plus 5 µM MRIA9).

注意

Hygroscopic

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable